NASDAQ: ADMAAdma Biologics Inc Stock
$8.48+0.36 (+4.43%)
Updated Jun 10, 2026
ADMA Price
$8.48
Fair Value Price
N/A
Market Cap
$1.97B
52 Week Low
$7.21
52 Week High
$22.20
P/E
12.29x
P/B
5.04x
P/S
4.17x
PEG
0.47x
Dividend Yield
N/A
Revenue
$509.86M
Earnings
$165.35M
Gross Margin
61.3%
Operating Margin
41.89%
Profit Margin
32.4%
Debt to Equity
0.7
Operating Cash Flow
$128M
Beta
1.21
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ADMA Overview
ADMA Biologics, Inc. functions as a biopharmaceutical company specializing in the development, manufacturing, and commercialization of advanced biologic therapies derived from blood plasma. These specialized products are engineered to address immune system disorders and infectious diseases, catering to markets across the United States and internationally. Their current product portfolio includes BIVIGAM and ASCENIV, both intravenous immune globulin (IVIG) treatments prescribed for primary humoral immunodeficiency (PI). Additionally, the company offers Nabi-HB, utilized for immediate treatment following acute exposure to the Hepatitis B virus and other specified exposures. Beyond its existing offerings, ADMA is actively developing a pipeline of new plasma-derived therapeutics. This includes immunoglobulin products specifically targeting the prevention and treatment of S. pneumonia infections. The company also oversees its own facilities for source plasma collection. Product distribution is managed through a comprehensive network involving independent distributors, sales agents, specialty pharmacies, and other alternative healthcare providers. ADMA Biologics, Inc. was founded in 2004 and maintains its corporate headquarters in Ramsey, New Jersey.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ADMA's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
ADMA
Ranked#68 of 462
Ranked#68 of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $229.63 | A | |
| $52.58 | A | |
| $15.66 | A |
Be the first to know about important ADMA news, forecast changes, insider trades & much more!
ADMA News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ADMA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ADMA ($8.48) is trading below its intrinsic value of $9.67, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ADMA is good value based on its earnings relative to its share price (12.29x), compared to the US market average (14.77x)
P/E vs Market Valuation
ADMA is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more ADMA due diligence checks available for Premium users.
Valuation
ADMA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
12.29x
Industry
18.33x
Market
14.77x
ADMA is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
ADMA is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
ADMA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
5.04x
Industry
4.71x
ADMA is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ADMA price to earnings growth (PEG)
For valuing profitable companies with growth potential
ADMA is good value based... subscribe to Premium to read more.
PEG Value Valuation
ADMA's financial health
Profit margin
Revenue
$114.5M
Net Income
$45.3M
Profit Margin
39.6%
ADMA's Earnings (EBIT) of $213.57M... subscribe to Premium to read more.
Interest Coverage Financials
ADMA's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$665.2M
Liabilities
$274.9M
Debt to equity
0.7
ADMA's short-term assets ($511.17M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ADMA's short-term assets ($511.17M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ADMA's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ADMA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$58.2M
Investing
$2.4M
Financing
-$10.1M
ADMA's operating cash flow ($128.32M)... subscribe to Premium to read more.
Debt Coverage Financials
ADMA vs Biotech Stocks
Adma Biologics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.